Eli Lilly’s CGRP migraine prevention med Emgality trailed its rivals onto the market, but it’s been a force in the dogfight for market share. Now, in an effort to learn more about how physicians choose between the med and its competitors, the company has started a real-world evidence study.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,